VectivBio Holding AG (VECT): Price and Financial Metrics
VECT Price/Volume Stats
| Current price | $16.85 | 52-week high | $16.98 |
| Prev. close | $16.85 | 52-week low | $4.25 |
| Day low | $16.80 | Volume | 130,400 |
| Day high | $16.88 | Avg. volume | 545,546 |
| 50-day MA | $14.67 | Dividend yield | N/A |
| 200-day MA | $9.71 | Market Cap | 573.24M |
VECT Stock Price Chart Interactive Chart >
VectivBio Holding AG (VECT) Company Bio
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for rare conditions. It develops Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as for SBS-IF in patients with colon-in-continuity anatomy. The company was incorporated in 2019 and is headquartered in Basel, Switzerland.
VECT Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 314.00% |
| 5-year | N/A |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | 76.48% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...